The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of the ERĪ± agonist GTx-758 on bone turnover markers in men with advanced prostate cancer.
Evan Y. Yu
Consultant or Advisory Role - GTx
Thomas E. Keane
Consultant or Advisory Role - GTx
Ronald Tutrone
No relevant relationships to disclose
Laurence Belkoff
No relevant relationships to disclose
Joel Bass
No relevant relationships to disclose
Franklin Chu
No relevant relationships to disclose
Mike Gambla
No relevant relationships to disclose
Franklin Gaylis
No relevant relationships to disclose
James Bailen
Consultant or Advisory Role - GTx
Robert H. Getzenberg
Employment or Leadership Position - GTx
Stock Ownership - GTx
Christopher Coss
Employment or Leadership Position - GTx
Stock Ownership - GTx
Michael L. Hancock
Employment or Leadership Position - GTx
Stock Ownership - GTx
James T. Dalton
Employment or Leadership Position - GTx
Stock Ownership - GTx
Mitchell S. Steiner
Employment or Leadership Position - GTx
Stock Ownership - GTx